Literature DB >> 21719263

[External radiation exposure and effective half-life in Lu-177-Dota-Tate therapy].

Jürgen Fitschen1, Bernd O Knoop, Rüdiger Behrendt, Wolfram H Knapp, Lilli Geworski.   

Abstract

The aim of the study was to estimate the external radiation exposure emitted by the patient to his surroundings after discharge. Being in compliance with legal requirements is especially important when doing multiple therapies. To estimate the effective half-life to be used quite realistically, the individual effective half-lives for 41 patients with 52 therapies were calculated. From the resulting histogram the maximum value was determined to be 100 h. Substituting the physical half-life by this maximum effective half-life results in dose estimates, which are lower but still conservative. In addition, the analysis of dose related parameters for patients who underwent multiple therapies demonstrates that the parameters estimated for the first therapy cannot be transferred to the subsequent ones.
Copyright © 2011. Published by Elsevier GmbH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719263     DOI: 10.1016/j.zemedi.2011.05.001

Source DB:  PubMed          Journal:  Z Med Phys        ISSN: 0939-3889            Impact factor:   4.820


  2 in total

1.  First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer.

Authors:  Jens Kurth; Bernd Joachim Krause; Sarah M Schwarzenböck; Carina Bergner; Oliver W Hakenberg; Martin Heuschkel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-03       Impact factor: 9.236

2.  External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies.

Authors:  J Kurth; B J Krause; S M Schwarzenböck; L Stegger; M Schäfers; K Rahbar
Journal:  EJNMMI Res       Date:  2018-04-12       Impact factor: 3.138

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.